Andamertinib as First-line Treatment for NSCLC With EGFR PACC or EGFR L861Q Mutation
Status:
NOT_YET_RECRUITING
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter phase IIclinical trial designed to evaluate the efficacy, safety, and tolerability of Andamertinib (phase II) in previously untreated participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR PACC mutations or EGFR L861Q mutations.